Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Gujarat Themis Biosyn has scheduled an Extra-Ordinary General Meeting (EGM) on August 22, 2026. Shareholders will consider and approve resolutions for a private placement of non-convertible debt securities, material related party transactions with promoter/promoter group entities, and amendments to the Articles of Association.
Aug 02 2026 00:32:42
Gujarat Themis Biosyn Ltd - 506879 - Notice Of Extra-Ordinary General Meeting On 22.08.2026
Gujarat Themis Biosyn is calling an EGM on August 22, 2026, to approve several key financial resolutions. These include issuing non-convertible debentures up to Rs.1,500 crore and obtaining borrowings up to Rs.450 crore, along with Rs.1,000 crore guarantees from promoter group entities. These actions are intended to support strategic acquisitions, investments, and working capital needs, driving future growth.
Jul 31 2026 22:02:18
Gujarat Themis Biosyn Ltd - 506879 - Board Meeting Intimation for Approval Of Un-Audited Financial Results And Limited Review Report Of Statutory Auditor For The Quarter Ended 30.06.2026
Gujarat Themis Biosyn's Board is scheduled to meet on August 7, 2026. The agenda includes the consideration and approval of the unaudited financial results for the quarter ended June 30, 2026.
Jul 31 2026 21:19:13
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Newspaper Publication
Gujarat Themis Biosyn has initiated a postal ballot to seek shareholder approval for raising funds through a Qualified Institutional Placement (QIP) and private placement of non-convertible debentures (NCDs) or other debt securities. E-voting will be conducted from July 24 to August 22, 2026, with results by August 25, 2026.
Jul 24 2026 13:55:06
Gujarat Themis Biosyn Ltd - 506879 - Shareholder Meeting / Postal Ballot-Notice of Postal Ballot
Gujarat Themis Biosyn's postal ballot seeks shareholder approval for a QIP of up to ₹1,000 crores and private placement of NCDs/debt securities up to ₹1,500 crores. These funds are intended for growth, working capital, and debt repayment.
Jul 23 2026 22:58:38
Gujarat Themis Biosyn Ltd - 506879 - Revised Disclosures of reasons for encumbrance by promoter of listed companies under Reg. 31(1) read with Regulation 28(3) of SEBI (SAST) Regulations, 2011.
Gujarat Themis Biosyn's promoter, Pharmaceutical Business Group, created an indirect encumbrance on 5,12,40,000 shares (47.02% of equity capital). The encumbrance secures Rs. 135 crore debt, primarily for personal use by promoters and PACs.
Jul 21 2026 17:38:07
Gujarat Themis Biosyn Ltd - 506879 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Gujarat Themis Biosyn's promoter, Pharmaceutical Business Group, created an indirect encumbrance on 5,12,40,000 shares (47.02% of equity capital). The encumbrance secures Rs. 135 crore debt, primarily for personal use by promoters and PACs.
Jul 21 2026 17:26:17
Gujarat Themis Biosyn Ltd - 506879 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Gujarat Themis Biosyn's promoter, Themis Medicare Limited, released a pledge on 1.65 million equity shares, equivalent to 1.51% of the total share capital. The shares were originally pledged for loan repayment and were released on July 8, 2026.
Jul 21 2026 11:16:54
Gujarat Themis Biosyn Ltd - 506879 - Revised Disclosures under Reg. 31(1) and 31(2) of SEBI (SAST) Regulations, 2011.
Gujarat Themis Biosyn's promoter, Pharmaceutical Business Group (India) Limited, released a pledge on 25.45 lakh equity shares. This reduces the promoter's pledged holding from 2.34% to 0.004% of the total share capital, signaling deleveraging.
Jul 21 2026 10:46:53
Gujarat Themis Biosyn Ltd - 506879 - Announcement under Regulation 30 (LODR)-Credit Rating
Gujarat Themis Biosyn's long-term and short-term bank facilities have been placed on 'Rating Watch with Negative Implications' by CARE Ratings due to concerns surrounding its major acquisition plans totaling ~Rs.3,000 crore. The company also announced plans to raise Rs.1,000 crore via QIP for funding.
Jul 20 2026 17:51:44
Read More